With LSD making a cultural and scientific comeback, a guide to using LSD is needed to help steer first-timers in the right direction. Many people are yearning to experience the mind-altering effects of this elusive yet celebrated drug that has garnered an eclectic mix of fans from the likes of Michel Foucault to Steve Jobs. […]
The decriminalization of psychedelics in Canada is arguably the next logical step after the legalization of cannabis. However, drug reform was not a major highlight of the most recent Canadian elections. To be fair, it almost never is. Nevertheless, it continues to disappoint to see major political parties yet again ignore the popularity and potential […]
Psychedelics can be mind-opening, life-changing portals that propel you into another reality of introspective thought, deep connections, and beautiful discoveries… but if used incorrectly, they can be scary and borderline traumatizing. That said, they don’t need to be avoided or prohibited, as entheogens have been a part of human culture for millennia. Responsible and informed use of these compounds is crucial – just be sure that when prepping for your psychonaut adventure, you respect their psychedelic plant power and avoid some common mistakes that can make or break your trip.
Psychedelics are fun, but if you make any of the following mistakes before or during your trip, things can get too crazy, really fast. Make sure to follow our guide to ensure a positive trip, and to learn more about rapidly-growing psychedelic industry, subscribe to The Psychedelics Weekly Newsletter.
What Are Psychedelics?
Psychedelic drugs, also referred to entheogens, are a subset of hallucinogens which contain compounds that can alter perception. The term entheogens come from Greek and can be roughly translated to mean “building the God within”. The high produced by these types of drugs is known as a ‘trip’, and can include various types of visual, auditory, and sensory hallucinations. The intensity of a trip can vary dramatically based on the specific compound and dose consumed. Sometimes, a user will experience no hallucinations at all, but rather a sense of general well-being, spirituality, and euphoria.
If you’ve ever heard someone mention a ‘bad trip’, this means they had some type of negative side effects or maybe even scary hallucinations. Physical symptoms of a bad trip can include but are not limited to: irregular heartbeat, nausea, chills, sweating, and anxiety. Dosing and setting, among other factors, can significantly impact a psychedelic trip, so you want to make sure that you’re doing everything possible to ensure an uplifting and beneficial high.
Are They Safe?
Psychedelics are generally regarded as safe. According to the results of a Global Drug Survey that polled 120,000 regular drug users, magic mushrooms were the safest recreational drug, along with cannabis. Their method at determining user safety was by comparing the drug used to the amount of required emergency room visits. Only 0.2% of the nearly 10,000 mushroom users surveyed had ever required emergency care, compared to the 1.0% of those using harder drugs like ecstasy or cocaine.
Good Trip Guaranteed: Common Mistakes to Avoid on Psychedelics
Again, just because psychedelic drugs are typically safe that doesn’t necessarily mean you’ll have a perfect experience with them. When partaking, it’s very important to set the mood beforehand to make sure everything goes smoothly and reduce your likelihood of having a bad trip. Avoiding the following mistakes will ensure that your experience with psychedelics is a positive one
Pick the right setting
Psychologist and author, Timothy Leary, could not emphasize it more… “set and setting” are of utmost importance when it comes to having a happy and therapeutic psychedelic trip. The general consensus is that it’s best to avoid unfamiliar situations, especially if you’re a novice user, and you should do everything possible to construct a safe and relaxing tripping environment BEFORE you start your adventure.
Make sure you’re in good company
At best, being around bad company or people that make you uncomfortable can be awkward and unpleasant. At worst, hanging out with the wrong people while tripping can become a literal nightmare complete with terrifying hallucinations. I don’t know about you, but for me, vibes are everything. If I get bad vibes from someone when I’m sober, you had better believe those negative feelings will be amplified if I’m on psychedelic drugs. To make sure you have a peaceful experience, you absolutely must surround yourself with people you trust and feel completely safe around.
Do NOT Use Hallucinogens with Other Substances
Psychedelic drugs are best used alone, unless of course you choose to smoke a little bit of cannabis along with them, which can have positive effects. Harder drugs and alcohol can be dangerous as they can magnify disorientation and physical symptoms associated with bad trips (nausea, chills, etc.), and some believe that combining these types of substances with entheogens can lead to violent thoughts and hallucinations.
Your Mood Impacts Your Trip
If you’re in a bad mood beforehand – feeling anxious, nervous, stressed, scared, or going through some sort of existential crisis – you might want to hold off on the psychedelics. Sure, when used therapeutically in a clinical setting, they can change your thoughts for the better. But if you’re inexperienced and grappling with dark thoughts, hallucinogens can amplify these and put you in a dangerously negative state of mind.
When planning your trip, it’s important to keep in mind that certain hallucinogens – mushrooms and LSD, for instance – can produce highs that last for up to 8 hours. Make 100 percent sure that you have enough time to complete your trip and come down from it properly without any type of activity or responsibility getting in the way. If you feel like you’re rushing and have too near of a cutoff time before getting back to reality, you could end up with a veil of dread and anxiety over your experience.
All in all, taking psychedelics successfully is not complicated or daunting in any way if you avoid making the above mistakes. Just be sure to keep a few things in mind, get your setting and company right, and don’t mix psychedelics with stronger drugs, and you can almost guarantee that your trip will be open, joyous, and transformative; rather than the complete opposite. Have you ever had a bad trip on psychedelics, and if so, was it related to any avoidable mistakes? We’d love to hear your thoughts, drop us a line in the comment section below!
Thank you for stopping by CBD TESTERS, your hub for all things relating to cannabis and psychedelics. Don’t forget to subscribe to The Delta 8 Weekly Newsletter for more articles like this one and exclusive deals on flowers and other products.
A recently published study suggests that high doses of cannabis can induce oceanic boundlessness, an altered state of consciousness commonly associated with psychedelic drugs. The mystical-like experience of oceanic boundlessness, which is characterized by a feeling of oneness with the universe, is the subject of ongoing research and could be connected to the potential therapeutic benefits of drugs including psilocybin and LSD.
Previous studies have shown that oceanic boundlessness experiences induced by psilocybin are associated with improvements in treatment-resistant depression.
Mitch Earleywine, a professor of psychology at the University at Albany in New York and lead author of the newly published research, told PsyPost that the study’s findings indicate cannabis could have similar “subjective effects that seem to underlie psilocybin’s antidepressant effects.”
The report, titled “Cannabis-induced oceanic boundlessness,” was originally released online earlier this year before its July publication in the Journal of Psychopharmacology.
Explaining Oceanic Boundlessness
In his book “The Psychedelic Renaissance,” U.K. researcher and psychiatrist Ben Sessa explains that oceanic boundlessness is a feeling of being at one with the universe, writing that “psychedelics can induce the experience of expansion beyond the traditional boundaries of personhood. One no longer defines oneself as simply a doctor, a father or mother, a husband or wife, a friend, neighbour or citizen; rather one is a leaf on a tree, a drop of water in a lake, a breath on the wind. One can feel part of a plethora of vibrating energy moving like electricity though all things, stretching back in time to the very origin of the universe.”
Research into oceanic boundlessness induced by psilocybin, a psychoactive compound found in magic mushrooms, has shown that the phenomenon may be linked to the mental health benefits of psychedelic drugs. Earleywine said those studies inspired the hypothesis that high doses of cannabis might induce a similar response.
“Once the psilocybin labs started emphasizing that oceanic boundlessness seemed to be the mechanism underlying the molecule’s antidepressant effects, nearly every cannabis fan couldn’t help but ask, ‘Hey! Doesn’t marijuana have comparable effects?’” said Earleywine.
“My students had already shown that ‘challenging experiences’ were common when folks ate more edibles than they intended to,” he added. “Asking folks if they thought cannabis also produced these oceanic boundlessness effects seemed an obvious next step.”
To conduct the study, researchers recruited a group of 852 cannabis users and asked them to complete a survey about the subjective effect of their most intense THC experience. The survey included items from the oceanic boundlessness subscale of the Altered States of Consciousness Scale, a questionnaire frequently used in psychedelic research. Subjects also provided demographic information and answered questions about their cannabis use.
Earleywine’s research revealed that almost 20% of the study subjects scored higher than 60% of the maximum value on the oceanic boundlessness subscale, the level at which respondents are considered to have had a “complete” or “breakthrough” oceanic boundlessness experience. Previous studies with psychedelic drugs have indicated that complete oceanic boundlessness events are more closely associated with decreases in depression than “non-complete” experiences.
More Study Needed
The rate at which cannabis induced a complete oceanic boundlessness experience was “significantly smaller than estimates from formal psilocybin trials.” However, the investigators noted that a controlled study into the ability of cannabis to induce the state could produce a higher rate of achieving oceanic boundlessness and called for further research into the issue.
“Formal protocols that borrow from psilocybin research, including the use of stated intentions, psychological support, music, and an eye mask, might enhance the rates of THC-induced breakthrough, potentially leading to therapeutic effects,” the researchers wrote in the study. “In addition, since THC’s initial pharmacological impact varies from psilocybin’s, comparing the two in randomized clinical trials might answer important questions related to the role of subjective experiences in psychoactive-assisted psychotherapy.”
The study offers preliminary data on the potential for cannabis to generate mystical-like experiences including oceanic boundlessness. But more research including clinical trials will be needed to determine if THC-induced oceanic boundlessness can have beneficial therapeutic effects on mental health, Earleywine says, particularly in light of potential negative effects that have been associated with cannabis use and depression.
“We need to bring folks into the lab to see if these effects are real, then get approval for a clinical trial,” he said. “I don’t recommend the home game. Cannabis can make depression worse for some people, or so it seems.”
June 3 is World Bicycle Day. The bicycle is not just a sustainable mode of transportation used the world over, it’s also a symbol of human advancement — in more ways than one On an otherwise ordinary April afternoon in 1943, a chemist ingested 250 micrograms of LSD and rode his bike home. He was […]
Just like cannabis gradually became a regular part of the mainstream conversation during the last decade, over the next few years we can expect to hear much more about psychedelics – everything from medical benefits to legalization efforts, societal views to current studies, and beyond. Given the safe and natural element to using these types of compounds, it’s no surprise that psychedelics are following the same path as cannabis: decriminalization and eventual re-legalization on the basis of scientific research and cultural acceptance.
Psychedelic research and legalization is a hot topic right now, and of all the psychedelics, THC is still the most popular one. For THC users who have a problem with the anxiety or experience paranoia, delta-8 THC might be preferable. If you think you could benefit from this altered version of THC, take a look at our awesome delta-8 THC deals, and try it out for yourself.
What are Psychedelics?
Psychedelic drugs are a subset of hallucinogens. They contain psychoactive compounds that are capable of altering a person’s mood, perception, and cognition; sometimes permanently. The active compounds are usually found in nature, like psilocybin or mescaline, but they can also be manmade, like LSD.
Psychedelics are known for causing ‘trips’, which is what the high is referred to. When a person is tripping, they may have altered perceptions of the world around them. Many people believe this is limited to visual and auditory hallucinations, but it can also include feeling, tasting, and smelling things that are not real, as well as a heightened sense of connection and understanding, and greater feelings of introspection.
The trips that people most commonly associate with these types of the drugs are the ones in which a state of hallucinogenic delirium is reached, but that is not always the case. Many times, it is more of an experience than a trip, and something can be learned and achieved psychologically with every small dose.
The word itself, ‘psychedelics’, was first used in 1957 to recognize substances that were said to open the mind, however, the more scientific term for them is ‘entheogens’. This term was adopted, not necessarily for the sake of being scientific, but rather to allow the field to operate without the stigma attached to psychedelics from the smear campaigns of the 1960’s. The term entheogen comes from Greek where it means ‘building the god within’.
Different psychedelics produce different trips. For example, with DMT you can expect a short high lasting less than 1 hour, whereas LSD, psilocybin, and mescaline trips can last up to ten hours. Some hallucinogens are more potent than others, like mushrooms vs acid. The active compounds are different in each drug so there is a lot of variation to the effects that can be felt.
Some people experience bad trips in which negative, or even scary, hallucinations are experienced, and/or a rapid heartbeat, sweating, nausea, disorientation, and fatigue occur. There is indication that the majority of these symptoms can be controlled through proper dosing. This is why most modern-day, therapeutic users of psychedelics consume the drugs in micro-doses.
Medical Research on Psychedelics
Just like cannabis, legalization and normalization of psychedelic drugs would be impossible if there weren’t some type of medical benefits to show on paper. Luckily, the research does exist, especially in the field of mental health. A study published just last month in the journal Nature Medicine found that MDMA-assisted therapy could be “a potential breakthrough treatment” for post-traumatic stress disorder.
Other studies have looked at psilocybin, the active ingredient in magic mushrooms, as a possible treatment option for clinical depression, and the results were incredibly promising. Additional research is underway to determine the effectiveness of numerous other psychedelics as well, including LSD and ketamine.
Most psychedelics are serotonergic, meaning the affect the serotonin receptors in our bodies. Many antidepressant drugs involve some type of serotonin signaling, although there are numerous different ways that substances can interact with these receptors. Using pharmaceuticals often leaves the patient with many unwanted side effects, whereas natural compounds are typically considered safer, when used correctly.
Psychedelics had a brief stint in modern medicine in the 1950s and several psychologists at the time were utilizing them to treat patients with depression and addiction, LSD in particular. They found it to be especially helpful in curbing alcoholism, which can be proven by this study in which it was reported that even 1 full year after treatment, subjects were still off the booze.
Known as ‘psychedelic therapy’ in the U.S. and ‘psycholytic therapy in the U.K., it was really catching on. However, when these compounds were added to the Schedule 1 narcotics list in both countries, the ability to research psychedelics, let alone utilize them in treatment plans, came to a screeching halt.
In recent years, we’ve seen a massive shift in the way the public, as well as healthcare and government agencies, view this class of drugs. The FDA itself has deemed both psilocybin and MDMA (magic mushrooms and ecstasy) as “leading breakthrough therapies” for depression and PTSD. This means that we can anticipate a rush in research and development for products containing these active ingredients in the very near future.
Psychedelic Legalization Efforts
The heavy regulation of psychedelics began in 1966, just as these drugs started making their way in the realm of recreational use. At the time, ‘recreational’ use of psychoactive substances was rooted in their ability to expand one’s consciousness. Psychedelic activists of today could very well be driven by similar motives, but the focus of their public campaigns is ‘safe, natural, alternative healthcare’ – a topic that many people have been showing greater interest in over the last decade.
Looking at it from a purely legal perspective, it not only makes sense, but it seems like the only logical way to tackle a subject like this one. Pushing for full legalization of highly intoxicating substances is already a pretty tall order, but if using the argument that our collective consciousness is suffering and in need of expansion, you can imagine that the movement wouldn’t gain much traction (regardless of how true sentiment that actually is).
Psychedelic legalization will undoubtedly face many of the same challenges we have seen time and time again in the fight for cannabis legalization. We know medical research fueled by cultural mainstreaming makes for a remarkably effective weapon against outdated regulations. But despite how far we have come on both of those fronts in the cannabis industry, it remains federally prohibited. And when looking at our current administration, we know that Joe Biden really has a bug up his you-know-what about cannabis, so it seems incredibly unlikely that we will see any kind of turnaround with psychedelic regulations on his watch.
Nevertheless, we know it’s in the cards and by the end of this decade it will be a booming industry. Numerous, cities, states and countries have relaxed their laws surrounding possession and use of psychedelics drugs.
Cultural Views on Psychedelic Legalization
Compared to cannabis, psychedelic have the unique advantage of being carrying less social stigma. Many advocates of psychedelic drugs are healers themselves, dedicated to conserving cultural traditions regarding the healing of pain and trauma through rituals that include psychedelic use – and this will be a huge contributing factor to eventual legalization.
From their initial emergence into the mainstream discussion, psychedelics have been positioned as a therapeutic drug, rather than recreational; as compounds that you use in micro doses to get only the psychological benefits without any of the psychoactive side effects; and as compounds that will soon be utilized in some of the most cutting-edge therapy sessions, by the most progressive practitioners.
Stigma still exists, as is the case with any intoxicating compound, but much of this stems from completely irrelevant fear; and luckily it’s nowhere as commonplace as it has been in years prior. Most people, even those who generally lean conservative, are adopting more liberal views when it comes to the use of certain substances, especially those that are found in nature. Plant-based healing is a much more popular concept now that in has been in our nation’s recent past.
In a big move for the psychedelic industry, a bill was recently passed by a second California Senate committee which would legalize the possession of numerous different forms of psychoactive drugs in the Golden State. The legislation, which was sponsored by Senator Scott Wiener (D), advanced through the Public Safety Committee earlier this month, followed by a pass from the Health Committee one week later. If this bill fully passes, an extensive list of psychedelics including psilocybin mushrooms, DMT, ibogaine, LSD, and MDMA would be legalized for adults aged 21 and older.
Additionally, the bill would call for the expungement of prior convictions for possession of psychedelic drugs, the same way the state is trying to expunge cannabis convictions; as well as redefining what paraphernalia will be lawful to possess and use with these newly legalized substances.
If this all sounds vaguely familiar it’s because California was also the first state to legalize medical cannabis use back in 1996, long before it was a frequent topic in any political discourse. The golden state is also the birthplace of most cultural cannabis trends over the last few decades. California has been at the forefront of cannabis legalization efforts since the early 1970s and is one of the first states to begin expunging prior cannabis-related convictions after Prop 64 passed in 2016.
“The war on drugs has been an abject failure because it is based on the false belief, the false notion, that criminalizing people, arresting them, incarcerating them for possessing, for using drugs, will somehow deter use and improve public safety,” commented democratic Senator Scott Wiener. “It has done neither.”
Oregon, Washington and Colorado are also very liberal states that have been working to change the national narrative on drug use, particularly cannabis and other psychedelics. Oregon became the first state in the United States to decriminalize the possession of all drugs. Possessing heroin, cocaine, methamphetamine and other intoxicating substances for personal use is no longer a criminal offense in Oregon. Those drugs are still against the law, as is selling them. But possession is now a civil – not criminal – violation that may result in a fine or court-ordered therapy, not jail.
The path to drug legalization can be bumpy, and taking psychedelics from illegal to medical-use-only to legal for adult-use will take some time. But based on current patterns, we can expect this will happen relatively soon. Just like cannabinoids, psychedelic compounds are the medicine of the future and when legalization does occur, there will be an industry boom like we’ve never seen before.
Thank you for stopping by CBDtesters.co, your #1 spot for the best cannabis-related news globally. Give the site a read-thru daily to stay on top of the exciting world of legal marijuana, and sign up to receive our newsletter, so you never miss a thing. News and deals in your inbox every week!
As the legal cannabis market booms, another class of drugs on the horizon is getting closer to legalization, with its own impending boom coming. And that means a whole new place for investment. So as MDMA, psilocybin, and DMT work their way through medical trials, here’s how to invest in this new medical psychedelics field.
Psychedelics are a subset of hallucinogenic drugs, which themselves are a subset of psychoactive drugs. Whether made in a lab like LSD, or found in nature like psilocybin or peyote, psychedelics are known for causing ‘trips’. When a person is tripping, they may have altered perceptions of the world around, experience/feel/taste/see/hear things that are not real (hallucinations), feel a heightened sense of connection to those around them, experience euphoria, feel a sense of spirituality and connectedness with the universe, and a greater sense of self-introspection. A large percentage of psychedelics are serotonergic, meaning they effect serotonin receptors in the brain, though they can do this in different ways.
Some drugs like DMT produce short trips of less than an hour in duration. While other drugs like LSD, psilocybin, and mescaline can cause trips that last for many hours, as many as eight or ten. Sometimes people experience bad trips in which negative, or even scary, hallucinations are experienced, and/or a rapid heartbeat, sweating, nausea, disorientation, and fatigue occur. There is indication that the majority of these symptoms can be controlled through proper dosing. In fact, many therapeutic psychedelic users consume the drugs in micro-doses.
All psychedelics are Schedule I in the Convention on Psychotropic Substances, a drug scheduling treaty which defines the legality of different compounds globally. Starting with the Staggers-Dodd bill in 1968 which illegalized LSD and psilocybin, and finishing with the placement in the Convention, making all such substances illegal to buy, sell, or consume, with no purported medical value.
Psychedelics have been used for thousands of years, all throughout the world, though their uses in medicine in the mid-1900’s, and proposed uses today, are generally different than the shamanistic/ritualistic way they were primarily used in history, although this is not to say that there were not traditions that did use psychedelics therapeutically. Technically, if a shaman is consuming ayahuasca to get rid of demons, I suppose that could be thought of as therapeutic anyway.
Medical psychedelics research
Psychedelics, particularly, LSD, were introduced to modern medicine around the 1950’s after Albert Hoffman synthesized the compound in Switzerland in 1938. Several psychotherapists at the time, like Humphry Osmond and Ronald Sandison caught onto the idea, bringing these treatments to England and America. Hoffman conducted, among other research and therapy, the Saskatchewan trials, and ultimately came up with the idea of ‘psychedelic therapy’ in which a single large dose of LSD was given along with therapy sessions.
‘Psycholytic therapy’ is what Ronald Sandison’s version became known as in the UK, with the difference being that Sandison’s treatment style was to do multiple sessions with smaller amounts of the drug that increased through the process. Both doctors found great success particularly with alcohol addiction. How much success? According to the Saskatchewan trials, as many as 40-45% of drinkers were still not drinking a full year after the therapy session.
Unfortunately, when the drugs were made illegal, all ability to continue such treatments ended, and the ability for research into the field was completely stymied, and did not pick up again until much more recently. However, to give an idea of the massive turnaround that has been going on when it comes to psychedelics, consider that the US’s Food & Drug Administration (FDA), singled out both psylocibin in 2019 and MDMA in 2017 as ‘breakthrough therapies’ for depression and PTSD respectively. Such a designation by the FDA is meant to speed up research and development for products deemed necessary for health.
This indicates a desire by a US government agency to not only test these drugs, but to get them to market. And they’re all schedule I right now. One exception to psychedelics all being schedule I, however, is magic mushrooms. Though its psychoactive components like psilocybin are Schedule I, and therefore illegal, the plants themselves are not outlawed, creating a bit of gray area in terms of mushroom use, cultivation, and production. This gray area could prove useful in the future.
What can be expected?
If you’re wondering why this matters, consider how massive – and growing – the legal cannabis markets are. Well, psychedelics offer many of the same medical benefits, especially psychologically, with possibly added abilities in other departments. And they’ve proven to be very safe. As an industry in which much of it is pharmaceutical to begin with, it’s a safe bet that these drugs are going to pick up quickly. Because the pharma world is sure to take a massive interest, it gives even more reason to invest in medical psychedelics now, before everything explodes.
So how much is it worth? I’m not the kind of writer who generally likes to get into these numbers. Every publication makes its own predictions, off its own information, and very rarely do these predictions seem to consider world changes. Whatever the size of the CBD industry was originally predicted to grow to a few years ago, that number would be invalid by now because it didn’t account for THC-based medicines growing in popularity, or legal markets, or psychedelics.
Imagine how much psychedelics could eat away at cannabis revenue. And not only that, any predictions of the future market size for psychedelics would have to take into account the still expanding cannabis markets (with more countries constantly legalizing in some form or another), and the question mark of what currently unforeseen factors could upend the trend a few years down the line. So, I’m not concerned with too many predictor numbers, but here’s just one, in order to get an idea what we’re dealing with.
PRNewswire, citing an analysis by Data Bridge Market Research, explained the forecast for 2020-2027, in which the field is expected to grow to $6.8 billion by 2027. It was worth just over $2 billion in 2019.
Best ways to invest in growing medical psychedelics field
Now that a certain barrier seems to be broken, more companies are conducting clinical trials, getting patents, and starting to get clearances for products. In fact, if you thought the psychedelics market was off limits, you’d be very much mistaken. Not only is this a growing market with a lot of possibility, but companies are already staking their claim, leaving room for you to start investing. So, if you like the idea of getting in on something before it explodes, consider investigating the following companies, and invest in the medical psychedelics field.
Much like with cannabis, Canada is quickly establishing itself as a leader in medical psychedelics, with the top companies coming out of this country. In the first half of 2020, $150 million USD was raised by six different companies: Mind Medicine, COMPASS Pathways, Field Trip Psychedelics, ATAI Life Sciences, Orthogonol Thinker, and Numinous Wellness. Mindmed and Numinous are already publicly listed companies. This is an early stage entry for investors. In fact, to give an idea of how seriously Canada is taking this, the first exchange traded fund – The Horizons Psychedelic Stock Index ETF, made its debut in January. ETF’s are like regular asset exchanges, except that they include a mix of stocks, commodities, and bonds. This exchange is solely for psychedelics.
The CEO of the fund, Steve Hawkins, said that while larger pharmaceutical companies have been admitted to the fund, the idea is to keep it mainly for smaller psychedelics companies. Companies can be added to the fund if they can tick the following boxes: be a part of a regular US or Canada-based stock exchange, be a biotechnology company focusing on medical psychedelic research, be a producer and/or supplier of psychedelic medicines, and be a company that works within the general supply chain for psychedelic medications.
Biggest names so far
When it comes to emerging fields and investing, the majority of people will never get there preemptively, and will instead act by reaction. For anyone who wants to get in on it before the top blows off, the following companies currently provide the best prospect for future growth, expansion, approval, and ability for revenue. These names should be noted, they will likely be bringing you the first approved medical psychedelic products, and for anyone looking to invest in this rapidly growing field of medical psychedelics, they stand out as the best options so far.
Mind Medicine is one of the furthest along when it comes to getting a product out there. It’s a pharmaceutical company that specifically works to develop psychedelic medications. The company is currently in the middle of six different trials on drugs like MDMA, LSD and DMT. In January of 2021, MindMed announced the first ever clinical trials to involve a combination of MDMA and LSD, with company president Dr. Miri Halperin Wernli stating:
“I believe that when LSD and MDMA are taken together they have exceptional potential to open a window into our mind which will awaken it to new levels of awareness by changing the fluidity of the state of consciousness, amplifying changed perceptions, intensifying emotions, and stimulating novel thoughts. It is like a gateway to a multidimensional universe.”
When it comes to MDMA trials, MAPS – Multidisciplinary Association for Psychedelic Studies, is also making its way to approval. MAPS entered phase III of its trials into MDMA for PTSD, and aligned this phase with the FDA according to a Special Protocol Assessment made directly with the FDA. This means that so long as the trials show clinically significant results, the study will already check all FDA regulatory boxes, and make it that much easier for approval.
However, a psychedelic drug has technically already been approved by the FDA. In March of 2019, Johnson & Johnson’s Spravato got approval. The spray treatment is considered for those who have not received a benefit from at least two separate anti-depressants. Spravato is a drug that’s a chemical cousin of the drug ketamine, which is classified as a dissociative drug, but also as a psychedelic. The medication is meant for severe depression.
There are tons of companies popping up. Apart from the companies already listed, prospective investors should check out Champignon Brands, Hollister Biosciences, Better Plant Sciences, Captiva Verde Land, Core One Labs, Cybin, Empower Clinics, Ehave, Jazz pharmaceuticals and EGF Theramed Health. All of these companies are associated in some way or other with the production of psychedelic medications. And while I have yet to see it mentioned in an article, it seems to me that what might upend everything I just said, is the ability to cultivate magic mushrooms.
Something to consider
Much like cannabis, mushrooms come with the ability for easy self-cultivation, as well as large scale cultivation. People who invest in today’s cannabis cultivation already know the value of having growing fields. Imagine the same thing, but with mushrooms. I personally believe that the biggest way in the future to invest in medical psychedelics, will be through the growing of mushrooms.
As stated, this is my opinion, and has not been discussed much as far as I can tell. This is not shocking though, and really doesn’t mean much, as this topic is also an undesirable one for any biotech or pharmaceutical company that – much like with cannabis – would much prefer you know nothing about how to do this on your own. And much like cannabis, it’s easy enough to learn how for anyone who needs some help getting started. Plus, since cultivation and sale of the mushrooms themselves is actually legal in many places, it’s way more legal to grow a field of mushrooms in much of the world, than to grow a field of cannabis.
How to invest in Medical Psychedelics – Conclusion
That the medical psychedelics field is coming is not as much up for debate as many would believe. It might be growing in the shadow of the cannabis market, and being kept quiet until the ability for large scale monetization is possible, but it’s coming, and it will be big. For those who want to invest in the growing medical psychedelics field, getting in now is probably the best idea, and with all the new companies popping up every day, it’s sure to become a heated race very soon.
Hello and welcome to CBDtesters.co, the best location to get up-to-date cannabis-related news from around the globe. Join us frequently to stay in-the-loop on the exciting world of legal cannabis, and sign up for our newsletter so you always know what’s going on.
Disclaimer: Hi, I’m a researcher and writer. I’m not a medical professional, I have no formal legal education, and I’ve never been to business school. All information in my articles is sourced from other places, which are always referenced, and all opinions stated are mine, and are made clear to be mine. I am not giving anyone advise of any kind, in any capacity. I am more than happy to discuss topics, but should someone have a further question or concern, they should seek guidance from a professional in the relevant field for more information.
Yup, there’s a vape ban in the USA, but that doesn’t mean we can’t get you any delta-8 THC products at all. Delta-8 THC is the less psychoactive THC compound that produces less anxiety and panic for users. Check out the great delta-8 THC deals we’ve got, and start experiencing delta-8 in a whole new way.
For several decades, psychedelics have been uniformly outlawed, with massive campaigns from the late 1900’s used to raise fear and controversy over their effects. Now, as the world acclimates to the medical and recreational use of cannabis, psychedelics are being looked at once again for their medical benefits. In fact, one of the leading points of research is the use of LSD to treat mental illness.
When it comes to psychedelics, cannabis is one of the most popular, and its not hard to see why. THC has medical benefits and makes people feel good. However, for some people, regular THC is just too much. If you’re one of those people, check out our Delta-8 THC deals, and experience THC with slightly less psychoactive effect, and less anxiety.
What is LSD?
LSD, known more scientifically as Lysergic acid diethylamide, is a hallucinogenic psychedelic drug, which was first synthesized in 1938 by Swiss chemist Albert Hoffman. He was also the first person to experience its effects when he accidentally ingested a small amount in 1943. As a psychedelic, it is known for altering perception, feelings, and thoughts, as well as causing visions and sensations that are not actually there (hallucinations). LSD is in a class of drugs called ergolines which are often used to treat disorders like Parkinson’s. Unlike some compounds like DMT, LSD is manmade, though derived from the ergot fungus.
How exactly LSD works to cause the effects its associated with, is still not completely defined. However, certain aspects have been found in research. In one study put out in 2017 from the University of North Carolina, it was found that LSD interacts with serotonin receptors. Serotonin is a neurotransmitter that plays a big role in mood and brain communication. The particular receptor it effects is called 5-HT2AR. One of the interesting things that happens when LSD attaches to this receptor, is that the receptor closes over the molecule, preventing it from leaving quickly. This could very well explain why the drug can last for many hours, even after it has left the bloodstream.
The serotonin receptor it attaches to can activate two signaling pathways through G-proteins and β-arrestins within cells. With LSD, it primarily works through the β-arrestins. The researchers on this study found that different drugs in the ergoline group effect serotonin receptors differently, and found evidence that the compounds themselves can modify the structure of the receptor in order to activate different effects.
There has actually been plenty of research into how LSD can aide in the treatment of mental illness. Back in 2014, a randomized, double-blind, placebo-controlled study was done to investigate how safe and effective LSD is in treating the anxiety experienced by patients with life-threatening illnesses.
12 patients were used in the study, and they were given drug-free psychotherapy sessions, along with two psychotherapy sessions with LSD. A two-month follow-up showed a positive trend according to the (STAI) State-Trait Anxiety Inventory in terms of reductions in trait and state anxiety. The reductions in anxiety related to the LSD were sustained for 12 months. No serious adverse effects were noticed, and minimal adverse effects subsided within one day. The overall outcome of the study was LSD safely decreased anxiety.
In a systematic review of LSD in psychiatry, 11 studies were identified concerning LSD and mental health that consisted of randomized and controlled clinical trials. These were done between the years of 1950-1970 when it was not illegal to use LSD in medical testing, and when LSD was regularly studied for use with addiction, anxiety, depression, and psychosomatic diseases. As part of the 11 studies that made the cut, 567 subjects were administered LSD in doses of 20 to 800 micrograms. The overall finding was that LSD has positive results in psychiatric symptoms, particularly for alcoholism. A grand majority of the study authors from the review cited positive, if short-term, improvements. This was not always seen in long-term follow-ups.
LSD in the treatment of mental illnesstoday
Yet another systematic review was done on studies into LSD from after 1970. This review, called the Modern Clinical Research on LSD was published in 2017. The review looked at five recent studies in London, Zurich and Basel. All studies were placebo controlled. The London studies were single-blind, non-randomized, the Switzerland studies were randomized, double-blind. In all studies, low-moderate doses of LSD were used between 40-80 micrograms. (It takes about 100-200 micrograms for a full LSD effect).
In terms of subjective effects according to validated psychometric scales, the response in controlled settings was mainly positive. Average group ratings for liking the drug and having positive effects reached 90% of the maximum possible on the VAS scale after 200 micrograms had been administered. At 200 micrograms, only a small percentage increase was made for the average of those who had a negative drug effect (<25%), however negative ratings did go up with the increase.
No high levels of anxiety or panic occurred, necessitating no sedation of patients to stave off negative effects. The main feelings experienced during testing were: bliss, altered perceptions, audiovisual synesthesia (think crossed wires and mixed-up responses), and derealization and depersonalization in positive ways. Higher doses included more insightfulness.
In terms of the synesthesia, LSD produced spontaneous experiences, indicating it alters spontaneous processes, rather than creating an induced response. At under 100 micrograms, LSD promoted suggestibility, and at 200 micrograms it inspired mystical experiences during psychotherapy combined with LSD. Similar studies that have been done on psilocybin have shown that more intense mystical experiences are tied to long-term positive benefits.
However, these mystical effects were correlated at a high level with blissful states as well, meaning the long-term response could be more related to blissful experiences than mystical ones. In these studies, LSD promoted feelings of happiness, well-being, openness, closeness to other people, and trust.
In terms of negative effects, they generally didn’t last more than 10-24 hours, and included headache, difficulty with concentration, decrease in appetite, dizziness, dry mouth, nausea, exhaustion and feeling unbalanced. No severe adverse responses were noticed in any of the modern testing. LSD, in general, is considered non-toxic physically.
Why is it illegal?
When looking at all the positive scientific research, and the lack of detrimental side effects, it starts to look very strange that LSD has been illegalized, while pharmaceutical medications to treat the same things often have lower success rates and harsher side effects. While the US government might stick with a tagline of psychedelics being dangerous and having no medical value, there is another underlying story which makes a bit more sense.
LSD and psilocybin were first illegalized in the late 60’s after a years long smear campaign which coincided with the Vietnam war. America was off fighting a battle that didn’t technically involve it, and causing a massive death toll, and unspeakable and unnecessary violence and destruction to residents of Vietnam.
There was already a pretty heavy anti-war movement during that time. Want to speculate on how much bigger and harder to control that would’ve been if the country was focusing on the war as it should have been? The question of why America wanted to be in that war so badly is a whole debate in and of itself, but regardless of the ‘why’s, there are still some heavy truths. In 1994, a guy named John Ehrlichman, who had been the Assistant to the President for Domestic Affairs in Nixon’s administration, made this statement:
“The Nixon campaign in 1968, and the Nixon White House after that, had two enemies: the antiwar left and black people. You understand what I’m saying? We knew we couldn’t make it illegal to be either against the war or black, but by getting the public to associate the hippies with marijuana and blacks with heroin, and then criminalizing both heavily, we could disrupt those communities. We could arrest their leaders, raid their homes, break up their meetings, and vilify them night after night on the evening news. Did we know we were lying about the drugs? Of course we did.”
Is it really any wonder that in 1968 the US passed the Staggers-Dodd bill illegalizing both LSD and psilocybin? Or that in 1971 the Convention on Psychotropic Substances treaty gave it a Schedule I ranking? And is it really any wonder that this was heavily pushed for by richer countries with developed pharmaceutical industries, while poorer countries that didn’t have industries that could benefit the same way, were against the illegalization?
Things can change easily from good to bad, but they can also change from bad to good. Growing scrutiny towards agencies like the DEA for blocking scientific discovery in order to restrict access, and a renewed interest in medical testing, has re-opened the door which had been closed on LSD. Last month, the company MindMed even announced the beginning of the very first clinical trial ever to incorporate LSD and MDMA to test the possible benefits in dealing with mental illness.
Mindmed is a biotech company specializing in medicines and therapies using psychedelics. The trials are being done in Switzerland, which has been the base for a lot of psychedelics testing. Considering it’s a biotech company doing them, the logic answer would be that they want to make a product to sell eventually. My guess is, by the time they’re ready, it’ll be more legal globally to make LSD products to treat mental illness. After all, think about how fast the cannabis industry changed in the last few years.
The ongoing legalizations of cannabis, which is also a psychedelic, though a much less intense one, do signal a change in things. LSD has shown a spectacular profile for aiding in mental illness, with so few adverse reactions, that its silly what people are taking instead. It’s hard to say what the future holds, but it might very soon be the legalization for LSD medically.
Welcome to CBDtesters.co, your primary spot for all cannabis-related news around the world. Stop by frequently to stay on top of the ever-changing world of legal marijuana, and sign up to our newsletter so you’re always in the know!
As the battle for cannabis legalization continues globally, the re-acquaintance to its medical use has reopened the door for other drugs that have also been labeled as narcotics, or scheduled so that people have no access to their medical benefits. One of the major classes of drugs that has shown great promise therapeutically, is psychedelics. With a greater level of liberal acceptance, there has been a recent rise in the medical use of psychedelics.
What’s one of the most widely used psychedelic compounds on earth? THC! And not just the standard delta-9 THC that most people are familiar with. With the addition of delta-8 THC, users can choose how they want their experience to be. Want less psychoactive effect and less anxiety, then check out our Delta-8 THC deals and give the other THC a try.
What are psychedelics?
A psychedelic is a drug containing psychoactive compounds capable of altering a person’s mood, perception and cognition. This can include naturally occurring and man-made substances. Examples of psychedelics include: mescaline, which can be found in San Pedro cactus and peyote; DMT, one of the main ingredients in ayahuasca; LSD; and psilocybin, which is what makes magic mushrooms so magical.
Psychedelics are known to produce life-altering experiences, wherein the user can find insights into life and consciousness. It are these attributes that have been the main instigator for the recent rise in research of medical psychedelics.
Psychedelics, much like cannabis (which is technically a psychedelic), occur naturally in different plants around the globe, and have been used for millennia in different ceremonial, religious, and medical practices throughout history. Unlike cannabis, they were not all outlawed together in one sweeping move, but rather, became illegalized over time. In the US, the criminalization of psychedelics started in 1968 with the Staggers-Dodd bill which specifically illegalized LSD and psilocybin.
The word itself, ‘psychedelics’, was first used in 1957 to recognize substances that were said to open the mind, however, the more scientific term for them is ‘entheogens’. This term was adopted less to be scientific, however, and more to allow the field to operate without the stigma attached to psychedelics from the smear campaigns of the 1960’s. The term entheogen comes from Greek where it means ‘building the god within’.
History of illegalization
When it comes to the illegalization of cannabis, it is becoming understood more widely that there was more to it than a fear for public safety. The entire movement to illegalize was spearheaded in the government by Harry Anslinger, with media giant William Randolph Heart pushing the anti-hemp movement from outside, in an effort to kill the enemy of his paper industry.
Some might see it as a similar manner of business, when psychedelics were demonized in the 60’s and70’s, as when cannabis was in the 1930’s onward. In the case of psychedelics, much of the news, controversy, and general story around them, took place during the Vietnam war, and served as a good distraction from the horrible ridiculousness of that mess and the unnecessary violence and deaths that came from it. Think about what actually came out of that war. The nothingness that was accomplished in the face of the massive death toll that was taken. How easy is it to get your population to go along with such antics? And would focusing on the truth of it have made it a harder sell?
In 1970, the US congress passed the Comprehensive Drug Abuse Prevention and Control Act which enforced stricter measures for pharmaceutical companies, requiring stringent reporting, and better security of drug stocks. These aren’t bad things, of course, but they led to the current model of drug scheduling, which has, essentially and with much bias, ruled many drugs out.
The Single Convention on Narcotic Substances is a treaty that was formed out of international discussions concerning drug controls in 1970. This was followed up with the Convention on Psychotropic Substances in 1971, a similar treaty which also orders drugs into classes based on their potential level of harm and usefulness. In both treaties, schedule I is associated with the most dangerous drugs with no medical benefit, but a high addiction possibility, and schedule IV denotes safer drugs with medical purpose. Psychedelics took the schedule I spot in 1970, ruling out their use as medicines.
Putting psychedelics in this scheduling category seems to have been the result of industry issues, much like with cannabis. During the discussions for the treaties, bigger and more developed countries with bigger and more developed pharmaceutical industries, pushed for the illegalization of these natural compounds, whereas countries with less development, and which didn’t have competing industries, were not for their illegalization. As with cannabis, the bigger, stronger countries won out, and forced these decisions on everyone else.
In fact, in 1994, John Ehrlichman, the Assistant to the President for Domestic Affairs under Nixon, made this statement about the war on drugs that was fought under Nixon, highlighting an alternate reason for pushing anti-drug measures at that time:
“The Nixon campaign in 1968, and the Nixon White House after that, had two enemies: the antiwar left and black people. You understand what I’m saying? We knew we couldn’t make it illegal to be either against the war or black, but by getting the public to associate the hippies with marijuana and blacks with heroin, and then criminalizing both heavily, we could disrupt those communities. We could arrest their leaders, raid their homes, break up their meetings, and vilify them night after night on the evening news. Did we know we were lying about the drugs? Of course we did.”
And then it got worse. In 1984, President Ronald Reagan’s administration put out the Comprehensive Crime Control Act, which allowed for emergency banning of drugs by the government. This was put into effect the following year when the subject of MDMA came up, and was used to immediately illegalize it. And this despite a judge’s decision to schedule it as Schedule III, and allow it for medical use. This action entirely stymied any research progress into the drugs, and slowed the rise of medical psychedelics to a halt.
Psychedelics in history
As with anything else, putting together the history of psychedelic use in antiquity, is dependent on ancient texts, findings, and rituals. While there is a current rise in the use of medical psychedelics, this does not imply that they were used for the same exact purpose back then, as they are today.
One of the interesting finds related to psychedelics, is the discovery of a pouch in southwestern Bolivia, dated to a thousand years ago. The pouch contains traces of several psychedelic compounds including harmine and DMT (dimethyltryptamine) which denote the use of ayahuasca, bufotenine (from toad skin), and psilocin – another psychedelic constituent of magic mushrooms. The pouch also contained traces of cocaine and its metabolite benzoylecgonine, which would have likely come from coca leaves.
The discovery came from the Sora River Valley. The pouch – made of three fox snouts – was part of the contents of a leather bag, which mass spectrometry carbon dating has put between the years of 900-1100 CE. It is thought that because of the dating period, that the pouch likely belonged to a member of the Tiwanaku, which pre-dated the Incas. The use of ayahuasca denotes the earliest evidence of it that has been physically found.
The reason this part is interesting is because the two compounds that were found that ayahuasca is made from, come from two separate plants that work in combination to produce the effects. This means that the ancient population this comes from, was putting two plants together to gain a psychoactive effect that wouldn’t be felt if they were used on their own. Another interesting aspect of the find is that the plants used to make ayahuasca were not from that area, so whoever procured them, had to go out and find them somewhere else.
According to this study, Mayan culture is associated with the drinking of balché, a drink consisting of Lonchocarpus bark extracts that create a mildly intoxicating effect, which is strengthened through the use of honey. This was used in group ceremonies to reach intoxication. Peyote for mescaline, hallucinogenic mushrooms for psylocibin, and ololiuhqui seeds for lysergic acid amide (a precursor to LSD), were used by the Mayans, Aztecs, Olmecs, and Zapotecs.
During the period when the Olmecs were around, it was also customary to use bufotoxins which come from the skin of the Bufo spp. toad. At the same time, wild tobacco, Jimson weed, Salvia divinorum, and water lily were used for psychoactive effects. And while the exact use is arguable, mushroom stones dating back to 3,000 BC have been found in the Mesoamerican region in religious/ritual contexts which could indicate the use of mushrooms that far back. Archeological evidence of the use of peyote goes back as far as 5,000 years.
Mesoamerica isn’t the only location where psychedelic remains have been found. Researchers into psychedelic use in the near-East have turned up botanical remains in the form of residues, pollen, fibers and fiber impressions, and carbonized seeds. Where were they found? Traces of Blue Water Lily extract, a potent narcotic plant, were found in none other than Tutonkamen’s tomb from the 14th century BC. And in the late bronze age temple Kamid el-Loz in Lebanon, a storage jar containing 10 liters of Viper’s Bugloss was found, which is a very strong hallucinogen.
Things to consider…
One thing to take into account, is that there is a great amount of controversy over whether something like the use of ayahuasca can actually be traced back through history, with a lot of evidence pointing to confusing stories that come more from Western tourism, than actual history. Researchers into the topic have continually found a mesh of newer ideologies masquerading as old-school folklore as a means to sell a product. In fact, the whole idea of how ayahuasca is used today to treat mental illness, is not how it seems to have been used in history, when shamans took it to contact the supernatural, and battle evil beings.
Does this mean that psychedelics weren’t used in history? Of course not, but it does shed light on the idea that what we consider real history, might have been altered because of tourism. It should also be remembered that there are a lot of kinds of psychedelics that would have factored into different cultures and time periods. For example, the aforementioned study into hallucinogenic drug use in pre-Colombian Mesoamerica, which has findings based on archeological, ethno-historical, and ethnographic evidence, found plenty of indication of hallucinogenic drug use in that area, for that time period.
Rise of medical psychedelics
There is quite a bit of medical research into psychedelics, as well as historical evidence to its uses, going back thousands of years. According to the more recent medical research, psychedelics have shown a possible ability to aid in depression, PTSD, and with addictions. It should be remembered that cannabis itself is considered a psychedelic drug, with research into a multitude of categories including: insomnia, depression, neurodegenerative diseases, spastic disorders, inflammatory diseases and so on.
Psychedelics have not just been touted as a treatment for different mental illness. They have shown strength in dealing with neurodegenerative diseases like Alzheimer’s, and have even shown possibility in treating autoimmune disorders. If these benefits prove consistent over time, it will likely help boost the current rise in medical psychedelics.
However, despite all the relevant research into the useful benefits of these compounds, the DEA has continuously rejected information, and stood in the way of scientific progress. Kind of makes a person wonder what the agency is even there for. The report highlighted found that the DEA has continuously slowed down scheduling decisions, while increasing speed on banning drugs, in order to restrict all access.
It took an entire 30 years in all to respond to requests to reschedule marijuana, with gaps of 16 years, five, and nine in between requests and responses. The DEA even overruled its own judge to illegalize MDMA by putting it in schedule I. This, of course, has never gotten in the way of military testing of these compounds, which seems to be perfectly okay with the same agency.
With cannabis opening the door into the medical (and recreational) use of drugs like marijuana, the rise in medical psychedelics is sure to keep going. Just like with cannabis, it will likely be found over time, that the notions we have related to these drugs are way more attached to long-lasting smear campaigns, than the actual dangers they pose. And that just like cannabis, they can offer incredible medical benefits that have been suppressed for quite some time now.
Hello and welcome to CBDtesters.co, your #1 location for all cannabis-related news from around the globe. Join us regularly to stay on top of the world of legal cannabis, and check out our newsletter so you never miss a beat!